{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T18:15:15Z","timestamp":1715969715011},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2013,4,22]],"date-time":"2013-04-22T00:00:00Z","timestamp":1366588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,4,22]],"date-time":"2013-04-22T00:00:00Z","timestamp":1366588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1038\/leu.2013.123","type":"journal-article","created":{"date-parts":[[2013,4,22]],"date-time":"2013-04-22T06:38:20Z","timestamp":1366612700000},"page":"2253-2254","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Anti-oxidant vitamin E prevents accumulation of imatinib-resistant BCR-ABL1 kinase mutations in CML-CP xenografts in NSG mice"],"prefix":"10.1038","volume":"27","author":[{"given":"M","family":"Nieborowska-Skorska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Hoser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Stoklosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Skorski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,4,22]]},"reference":[{"key":"BFleu2013123_CR1","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/nrc2147","volume":"7","author":"JV Melo","year":"2007","unstructured":"Melo JV, Barnes DJ . Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007; 7: 441\u2013453.","journal-title":"Nat Rev Cancer"},{"key":"BFleu2013123_CR2","doi-asserted-by":"crossref","unstructured":"Eiring AM, Khorashad JS, Morley K, Deininger MW . Advances in the treatment of chronic myeloid leukemia. BMC Med 2011, 999.","DOI":"10.1186\/1741-7015-9-99"},{"key":"BFleu2013123_CR3","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1182\/blood-2005-03-1036","volume":"106","author":"SG Willis","year":"2005","unstructured":"Willis SG, Lange T, Demehri S, Otto S, Crossman L, Niederweiser D et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005; 106: 2128\u20132137.","journal-title":"Blood"},{"key":"BFleu2013123_CR4","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/sj.leu.2403426","volume":"18","author":"A Hochhaus","year":"2004","unstructured":"Hochhaus A, La Rosee P . Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 2004; 18: 1321\u20131331.","journal-title":"Leukemia"},{"key":"BFleu2013123_CR5","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1158\/0008-5472.CAN-10-3224","volume":"71","author":"CA Eide","year":"2011","unstructured":"Eide CA, Adrian LT, Tyner JW, MacPartlin M, Anderson DJ, Wise SC et al. The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile. Cancer Res 2011; 71: 3189\u20133195.","journal-title":"Cancer Res"},{"key":"BFleu2013123_CR6","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1182\/blood-2012-05-431379","volume":"121","author":"JS Khorashad","year":"2013","unstructured":"Khorashad JS, Kelley TW, Szankasi P, Mason CC, Soverini S, Adrian LT et al. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood 2013; 121: 489\u2013498.","journal-title":"Blood"},{"key":"BFleu2013123_CR7","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/j.chembiol.2011.11.001","volume":"18","author":"T Skorski","year":"2011","unstructured":"Skorski T . BCR-ABL1 kinase: hunting an elusive target with new weapons. Chem Biol 2011; 18: 1352\u20131353.","journal-title":"Chem Biol"},{"key":"BFleu2013123_CR8","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/j.1749-6632.2000.tb06182.x","volume":"899","author":"JM Gutteridge","year":"2000","unstructured":"Gutteridge JM, Halliwell B . Free radicals and antioxidants in the year 2000. A historical look to the future. Ann NY Acad Sci 2000; 899: 136\u2013147.","journal-title":"Ann NY Acad Sci"},{"key":"BFleu2013123_CR9","doi-asserted-by":"publisher","first-page":"4253","DOI":"10.1182\/blood-2011-10-385658","volume":"119","author":"M Nieborowska-Skorska","year":"2012","unstructured":"Nieborowska-Skorska M, Kopinski PK, Ray R, Hoser G, Ngaba D, Flis K et al. Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood 2012; 119: 4253\u20134263.","journal-title":"Blood"},{"key":"BFleu2013123_CR10","doi-asserted-by":"crossref","unstructured":"Bolton-Gillespie E, Schemionek M, Klein HU, Flis S, Hoser G, Lange T et al. Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. Blood 2013; (in press).","DOI":"10.1182\/blood-2012-11-466938"},{"key":"BFleu2013123_CR11","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood-2005-07-2815","volume":"108","author":"M Koptyra","year":"2006","unstructured":"Koptyra M, Falinski R, Nowicki MO, Stoklosa T, Majsterek I, Nieborowska-Skorska M et al. BCR\/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 2006; 108: 319\u2013327.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2013123.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2013123","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2013123.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T15:28:35Z","timestamp":1648740515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2013123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,22]]},"references-count":11,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["BFleu2013123"],"URL":"https:\/\/doi.org\/10.1038\/leu.2013.123","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,22]]},"assertion":[{"value":"22 April 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}